Mavatar at the World Economic Forum in Davos

We’re proud to share that Mavatar was present at this year’s World Economic Forum in Davos, where global leaders, innovators, and changemakers gathered to address some of the world’s most pressing challenges.

Our CEO, Johan Juhlin, represented Mavatar and joined influential voices from around the world in discussions centered on innovation, technology, and the future of healthcare. Events like these are crucial for building bridges across industries and borders, and for placing precision health at the center of the global conversation.

One of the highlights was #TheSwedishLunch, a standout gathering that brought together inspiring speakers from both Sweden and the international community. Ebba Busch delivered a compelling closing speech, powerfully positioning Sweden on the global stage. A special mention goes to Dr. Eva-Maria Hempe, who stood out as one of the day’s most inspiring voices.

Mavatar is proud to be part of a global movement driving positive change through AI and precision health. Davos reminded us once again of the importance of collaboration, vision, and bold ideas.

Mavatar is a global specialist in AI-driven precision medicine solutions for all diseases. Built on over 20 years of scientific research, Mavatar’s proprietary DINA (Deep Integrated Network Analysis) framework powers two flagship platforms: Mavatar Discovery for accelerating disease and drug research, and Mavatar Precision for delivering personalized treatment recommendations in clinical care. By creating digital twins of both patients and diseases, Mavatar enables data-driven decisions that improve treatment outcomes, optimize clinical trials, and reduce healthcare waste. Headquartered [insert location], Mavatar is driving the future of truly personalized, scalable healthcare across all disease areas. We envision a future where everyone receives personalized, predictive and effective care—powered by Mavatar.

The Company has partnerships with leading pharmaceutical companies, universities, and hospital systems. These collaborations focus on biobank studies and clinical trials, enabling research scientists to select the best drug candidates, suggest new uses for existing drugs, uncover new therapeutic targets, refine mechanisms of action, and match patients to innovative treatment options through point-of-care decision tools.

Connect with us on LinkedIn.